1. Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study. (October 2014) Authors: Goadsby, PJ; Grosberg, BM; Mauskop, A; Cady, R; Simmons, KA Journal: Cephalalgia Issue: Volume 34:Number 12(2014) Page Start: 986 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P.016 Reduction in migraine-associated burden over 24 weeks of treatment with eptinezumab in patients with chronic migraine. (June 2022) Authors: McAllister, P; Kudrow, D; Cady, R; Hirman, J; Ettrup, A; Minhas, S Journal: Canadian journal of neurological sciences Issue: Volume 49(2022)Supplement 1 Page Start: S11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P.017 Optimization of acute treatment and headache-related impact following eptinezumab initiated during a migraine attack: post hoc analysis of the RELIEF study. (June 2022) Authors: Buse, DC; Lipton, RB; Ettrup, A; Josiassen, MK; Lindsten, A; Cady, R; Omeragic, A; Duong, A Journal: Canadian journal of neurological sciences Issue: Volume 49(2022)Supplement 1 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P.027 Efficacy and Safety of Eptinezumab Initiated During a Migraine Attack: Results from the RELIEF Study. (November 2021) Authors: Winner, PK; McAllister, P; Chakhava, G; Ailani, J; Mehta, L; Ettrup, A; Krog Josiassen, M; Lindsten, A; Bougie, JK; Cady, R Journal: Canadian journal of neurological sciences Issue: Volume 48(2021)Supplement S3 Page Start: S27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P.032 Long-term safety and tolerability of eptinezumab in patients with chronic migraine: A 2-year, open-label, phase 3 trial. (November 2021) Authors: Kudrow, D; Cady, R; Allan, B; Pederson, S; Hirman, J; Meessen-Pinard, M; Schaeffler, B Journal: Canadian journal of neurological sciences Issue: Volume 48(2021)Supplement S3 Page Start: S29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P.033 Eptinezumab reduced acute medication use in patients with chronic migraine and medication-overuse headache: subgroup analysis of Promise-2. (November 2021) Authors: Marmura, MJ; Diener, H; Hirman, J; Cady, R; Brevig, T; Brunner, E; Minhas, S; Mehta, L Journal: Canadian journal of neurological sciences Issue: Volume 48(2021)Supplement S3 Page Start: S29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Search for point sources of ultra-high-energy photons with the Telescope Array surface detector. Issue 3 (3rd February 2020) Authors: Abbasi, R U; Abe, M; Abu-Zayyad, T; Allen, M; Azuma, R; Barcikowski, E; Belz, J W; Bergman, D R; Blake, S A; Cady, R; Cheon, B G; Chiba, J; Chikawa, M; di Matteo, A; Fujii, T; Fujita, K; Fujiwara, R; Fukushima, M; Furlich, G; Hanlon, W Journal: Monthly notices of the Royal Astronomical Society Issue: Volume 492:Issue 3(2020) Page Start: 3984 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗